renal cell carcinoma

AstraZeneca dumps phase 3 renal cell carcinoma program
Fierce Biotech
Thu, 10/24/19 - 10:23 am
AstraZeneca
savolitinib
renal cell carcinoma
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
Sat, 09/14/19 - 11:18 am
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Xynomic Starts Ph III Trial of Abexinostat in Renal Cell Carcinoma
CP Wire
Tue, 02/26/19 - 10:04 am
Xynomic
Abexinostat
renal cell carcinoma
Xynomic Starts Ph III Trial of Abexinostat in Renal Cell Carcinoma
Tue, 02/26/19 - 10:02 am
Xynomic
Abexinostat
renal cell carcinoma
Keytruda-Inlyta combo under Priority Review for first-line RCC
BioCentury
Fri, 02/15/19 - 10:34 am
Merck
Keytruda
Inlyta
renal cell carcinoma
FDA
priority review
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
Mon, 02/11/19 - 08:24 pm
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Wed, 09/19/18 - 11:27 am
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Exelixis Gets the Patients Eventually
Motley Fool
Mon, 08/6/18 - 11:47 pm
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
CP Wire
Wed, 06/6/18 - 09:42 am
Peloton Therapeutics
renal cell carcinoma
PT2977
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
Wed, 06/6/18 - 09:33 am
Peloton Therapeutics
renal cell carcinoma
PT2977
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Sun, 06/3/18 - 10:00 am
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Thu, 05/17/18 - 09:42 am
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Fierce Pharma
Thu, 04/12/18 - 11:46 am
Pfizer
renal cell carcinoma
kidney cancer
Inlyta
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
CP Wire
Tue, 04/10/18 - 03:21 pm
Pfizer
renal cell carcinoma
Inlyta
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Tue, 04/10/18 - 02:44 pm
Pfizer
renal cell carcinoma
Inlyta
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Thu, 01/4/18 - 10:04 pm
Exelixis
Cabometyx
renal cell carcinoma
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Fri, 08/18/17 - 12:01 am
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Wed, 07/12/17 - 10:05 am
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Here's Why AVEO Oncology Fell as Much as 12.7% Today
Motley Fool
Tue, 07/11/17 - 11:51 pm
Aveo Oncology
tivozanib
renal cell carcinoma
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda

Pages